China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

WorldChinaJapanIndiaSouth KoreaIndonesiaTaiwanThailandU.S.East AsiaChinaHong KongMacaoTaiwanMongoliaJapanSouth KoreaNorth KoreaSoutheast AsiaIndonesiaThailandMalaysiaSingaporePhilippinesVietnamMyanmarCambodiaLaosBruneiEast TimorSouth AsiaIndiaPakistanAfghanistanBangladeshSri LankaNepalBhutanMaldivesCentral AsiaKazakhstanUzbekistanTurkmenistanTajikistanKyrgyzstanOceaniaAustraliaNew ZealandPapua New GuineaPacific IslandsRest of the WorldMiddle EastRussia & CaucasusNorth AmericaLatin AmericaEuropeAfricaTrendingIran tensionsInflationTrump administrationArtificial intelligenceElectric vehiclesSupply ChainTaiwan tensionsBank of JapanImmigrationESGExplainerBusinessBusinessSemiconductorsAutomobilesEnergyTransportationRetailTravel & LeisureMedia & EntertainmentFood & BeverageFinanceElectronicsStartupsBusiness dealsMarketsMarketsEquitiesCurrenciesBondsCommoditiesPropertyIPOWealth ManagementTechTech#techAsiaChina techStartupsCryptocurrenciesDealStreetAsiaPoliticsPoliticsChinaJapanIndiaSouth KoreaIndonesiaTaiwanThailandU.S.East AsiaChinaHong KongMacaoTaiwanMongoliaJapanSouth KoreaNorth KoreaSoutheast AsiaIndonesiaThailandMalaysiaSingaporePhilippinesVietnamMyanmarCambodiaLaosBruneiEast TimorSouth AsiaIndiaPakistanAfghanistanBangladeshSri LankaNepalBhutanMaldivesCentral AsiaKazakhstanUzbekistanTurkmenistanTajikistanKyrgyzstanOceaniaAustraliaNew ZealandPapua New GuineaPacific IslandsRest of the WorldMiddle EastRussia & CaucasusNorth AmericaLatin AmericaEuropeAfricaEconomyEconomyChinaJapanIndiaSouth KoreaIndonesiaTaiwanThailandU.S.East AsiaChinaHong KongMacaoTaiwanMongoliaJapanSouth KoreaNorth KoreaSoutheast AsiaIndonesiaThailandMalaysiaSingaporePhilippinesVietnamMyanmarCambodiaLaosBruneiEast TimorSouth AsiaIndiaPakistanAfghanistanBangladeshSri LankaNepalBhutanMaldivesCentral AsiaKazakhstanUzbekistanTurkmenistanTajikistanKyrgyzstanOceaniaAustraliaNew ZealandPapua New GuineaPacific IslandsRest of the WorldMiddle EastRussia & CaucasusNorth AmericaLatin AmericaEuropeAfricaFeaturesTrading AsiaASEAN MoneyTech AsiaBusiness AsiaChina Up ClosePolicy AsiaBig in AsiaDatawatchInfographicsOpinionOpinionEditor-in-Chief's PicksThe Nikkei ViewLife & ArtsLife & ArtsLifeArtsMy Personal HistoryTea LeavesEat & DrinkDestinationsBooksObituariesWatch & ListenPodcastsVideoPhotosInnovent Biologics and Pfizer plan to collaborate on licensing, co-development and co-commercialization for 12 oncology programs. (Source photos by Reuters and Getty Images)WATARU SUZUKIMay 29, 2026 11:09 JSTSHENZHEN -- Chinese biotech firm Innovent Biologics on Friday said it had signed a licensing deal with U.S. pharmaceutical giant Pfizer for cancer drugs worth up to $10.5 billion.Read NextLatest on PharmaceuticalsSponsored ContentAbout Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.